NCT04522830已完成2 期
A Double-blind, Placebo-controlled, Phase 2 Trial of Sublingual Low-Dose Thimerosal in Adults With Symptomatic SARS-CoV-2 Infection
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Mean duration and severity of disease
研究概览
简要总结
Clinical trial to compare sublingual low does thimerosal in adults that have symptoms of SARS-CoV-2 Infection against placebo to show a difference in physical characteristics and viral levels.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •40 years of age or older
- •Provide written informed consent
- •Have a SARS-COV-19 diagnostic test with positive results
排除标准
- •Having an oxygen saturation level below 92% at baseline or currently on Oxygen therapy
- •Subjects currently hospitalized
- •Subjects who have received a COVID vaccination
- •Subjects with a diagnosis of immunodeficiency
研究组 & 干预措施
BTL-TML-COVID
Experimental
BTL-TML-COVID
干预措施: BTL-TML-COVID (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Mean duration and severity of disease
时间窗: Two days
Change from baseline in the physical component summary of the short form-36 Quality of Life Instrument
次要结局
- Incidence/Safety of Adverse Events(Baseline through 10 days)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous MalformationsCutaneous Venous MalformationsNCT06653842Palvella Therapeutics, Inc.15
进行中（未招募）
2 期
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's DiseaseHuntington DiseaseNCT05686551Hoffmann-La Roche301
招募中
2 期
ARISTOCRAT: Blinded Trial of Temozolomide +/- CannabinoidsCannabisBrain Tumor, RecurrentGlioblastomaBrain TumorNCT05629702University of Birmingham120
终止
2 期
An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-DiseaseChronic Graft-versus-Host-DiseaseOral Mucosal Disease Due to Graft-versus-host DiseaseNCT02123966Dana-Farber Cancer Institute10
终止
2 期
A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19COVID-19NCT04822701Boehringer Ingelheim5